×
Back to Agenda
LS03 Considering Benefit-Risk Assessment in New Drug Applications
Session Chair(s)
Mamoru Narukawa, PHD, RPH
Professor, Kitasato University, Japan
Speaker(s)
Katsuhiko Ichimaru
Review Director, Office of New Drug IV, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Yuko Asahara
Global Drug Development Div, Regulatory Writing and Submissions, Head, Novartis Pharma K.K., Japan
Mamoru Narukawa, PHD, RPH
Professor, Kitasato University, Japan
Have an account?